DC:ZEAL Zealand Pharma A/S
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. Its products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump-based diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes. The company has license agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; and Protagonist Therapeutics, Inc. Zealand Pharma A/S has collaboration agreements with Beta Bionics, Inc. to advance the development of a dual-hormone bionic pancreas utilizing Dasiglucagon and insulin; and UniQuest to identify novel peptide therapeutics inspired by venoms as potential treatments for gastrointestinal diseases. The company was founded in 1997 and is based in Copenhagen, Denmark.This company has ADRs that trade in the U.S. as the symbol ZEAL.
227.80 EUR
As of 03/24/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Biotechnology
Index country: Denmark
Country of incorporation: Denmark
IPO date: 11/24/2010
Stock exchange: Omx Nordic Exchange Copen
Exchange country: Denmark
Market cap: 3,937,977,600 EUR
Current dividend yield: 0.00%
Sedol: B0SDJB4